WEDNESDAY, Feb. 24 (HealthDay News) -- Nephron-sparing surgery confers the same degree of cancer control as radical nephrectomy when treating T1bN0M0 renal cell carcinoma, according to a study in the February issue of Urology.
Maxime Crépel, M.D., of the University of Montreal, and colleagues conducted the largest and only population-based study to date comparing the two types of surgery for the treatment of T1bN0M0 renal cell carcinoma. They analyzed data from 1988 to 2004 on 5,141 patients with the disease, of whom 275 (5.3 percent) were treated with nephron-sparing surgery and 4,866 (94.7 percent) underwent radical nephrectomy.
Five years after surgery, there were no statistically significant differences in cancer-specific mortality rates for the two groups of patients, the data revealed. The surviving proportion of patients was 91.4 percent in the nephron-sparing surgery group and 95.3 percent in the radical nephrectomy group, the researchers found.
"Taken together, our cancer-control rates add to the existing arguments favoring nephron-sparing surgery in patients with T1b lesions and suggest that nephron-sparing surgery use should be given equal consideration as radical nephrectomy in T1b patients," the authors write. "Nonetheless, future studies should systematically and prospectively compare cancer control and non-cancer control end points between nephron-sparing surgery and radical nephrectomy, in patients with either T1a or T1b lesions."
Copyright © 2010 HealthDay. All rights reserved.
|Previous: Extended-Release Mirapex Approved for Parkinson's Disease||Next: Iron Treatment for Anemia May Not Help After Hip Surgery|
Reader comments on this article are listed below. Review our comments policy.